Asset
QUILLAJA SAPONIN (QS-21)
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01687595 | phase2 | completed | 2012-10-29 | 2013-09-01 | Agenus Inc. | Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants With Recurrent Genital Herpes |
FDA applications (0)
This company has no applications containing this asset.